medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2014, Number 08

<< Back Next >>

Ginecol Obstet Mex 2014; 82 (08)

Management of ovarian metastasis from a lobular breast carcinoma

González-Macatangga M, Herrera M, De Santiago J, Zapardiel I

Language: Spanish
References: 18
Page: 563-569
PDF size: 381.92 Kb.


ABSTRACT

Ovarian metastatic breast cancer is infrequent and usually is originating from lobular carcinomas. It was found that the risk of developing an ovarian neoplasm is approximately doubled in women with a history of breast cancer. The finding of an adnexal mass in these patients involves a particular concern and requires a study. We report a case of a 67-yearold female diagnosed of an infiltrating lobular breast carcinoma. It is done lumpectomy and an axillary dissection of lymph nodes resulting 2 of 13 lymph nodes positives. She was treated with chemotherapy and hormone treatment staying the disease in remission for years. After she was admitted with malignant pleural effusion and pathological costal fracture. The ultrasound shows an increase of size of annexes and a CA125 and CA15.3 increased in the analysis. Bilateral oophorectomy was performed. The pathology was consistent with lobular breast carcinoma. Subsequently another income was required because of disease progression. Currently after almost two years since the adnexectomy, is in close monitoring by medical oncologists. Although the diagnosis of an adnexal mass in a woman who has had breast cancer is usually a benign finding, the risk in these women to develop a malignant ovarian pathology is increased compared to the general population. Therefore, although the patient remains asymptomatic, it is important an abdominopelvic exploration from time to time. If the ultrasound image of the adnexal mass is suspect, the CA125 is increased, or estrogen receptors are negatives in the original breast tumor, should be performed surgical evaluation.


REFERENCES

  1. Zafer T, Gokhan B, Ilker S, Nihal S, et al. Adnexal masses in women with breast cancer. Australian and New Zeland Journal of Obstetrics and Gynaecology 2012;52:266-269.

  2. Cáncer de mama heredo-familiar (2005). Disponible en http://www.prosego.com/index.php?option=content&ta sk=view&id=372&Itemid=42.

  3. Bigorie V, Morice P, Duvillard P, Antoine M, et al. Ovarian metastases from breast cancer. Report of 29 cases. Cancer 2010;116:799-804.

  4. Alvarado I, Picón G, García KG, Valencia R, Barroso S. Cáncer de mama metastásico: estudio clínico-patológico de 300 casos. Patología 2010;48:18-22.

  5. Simpkins F, Zahurak M, Amstrong D, Grumbine F, Bristow R. Ovarian malignancy in breast cancer patients with an adnexal mass. American College of Obstetricians and Gynecologists 2005;105:507-513.

  6. Hann LE, Lui DM, Shi W, Bach AM, et al. Adnexal masses in women with breast cancer: US findings with clinical and histopathologic correlation. Radiology 2000;216:242-247.

  7. Quan ML, Fey J, Eitan R, Abu-Rustum NR, et al. Role of laparoscopy in the evaluation of the adnexa in patients with stage IV breast cancer. Gynecol Oncol 2004;92:327-330.

  8. Engelstaedter V, Mylonas I. Lower genital tract metastases at time of first diagnosis of mammary invasive lobular carcinoma. Arch Gynecol Obstet 2011;283:93-95.

  9. Arrangoiz R, Papavasiliou P, Dushkin H, Farma JM. Case report and literature review: Metastatic lobular carcinoma of the breast an unusual presentation. Int J Surg Case Rep 2011;2:301-305.

  10. Hanagiri T, Nozoe T, Mizukami M, Ichiki Y, et al. Clinicopathological characteristics of invasive lobular carcinoma of the breast. Asian J Surg 2009;32:76-80.

  11. Guerriero S, Alcázar JL, Pascual MA, Ajossa S, Olartecoechea B. Preoperative diagnosis of metastatic ovarian cancer is related to origin of primary tumor. Ultrasound Obstet Gynecol 2012;39:581-586.

  12. Priego P, Rodríguez G, Reguero ME, Cabañas J, y col. Peritoneal carcinomatosis secondary to lobular breast cáncer. Rev Chilena de Cirugía 2007;59:223-228.

  13. Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. American College of Obstetricians and Gynecologists 1994;84:449-452.

  14. Mohseni H, Truong P, Hadjseyd M, Grimonpont A, et al. Uterine and ovarian metastases 28 years after the discovery of breast cancer. Presse Med 2003;32:67-69.

  15. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705-2712.

  16. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma. Analysis of 767 T1N0M0/T2N0M0 patients with long-term followup. Clin Oncol 1993;11:2090-2100.

  17. Tuthill M, Pell R, Guiliani R, Lim A, et al. Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis. Eur J Cancer 2009;45:2146-2149.

  18. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews 2003, Issue 2.




2020     |     www.medigraphic.com